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ABSTRACT
The purpose of this study was to determine whether supplementation with creatine monohydrate
is efficacious beyond the realm of its most popular use, which is in athletics. This study
investigated the safety of creatine supplementation in the general population. References were
collected through a review of PubMed and Scopus databases. Initial keywords searched were
creatine supplementation and creatine safety. Where possible, trials with human subjects were
utilized. Studies focused on creatine’s effects in athletes or weightlifting parameters were
eliminated. Topics were further narrowed down by conditions with the most amount of research
and medical concerns recognized as common to primary care. Creatine supplementation showed
potential benefits in treatment for major depressive disorder, diabetes, bone density, and
osteoarthritis. Mild weight gain due to the osmotic effect of creatine was the only side effect
noted in the evidence. Kidney function is not affected by creatine supplementation. Creatine
supplementation has potential benefits for many different patient populations, with the only side
effect of creatine supplementation being mild weight gain due to the osmotic effect of increased
creatine saturation in the body. Clinicians should consider creatine supplementation without fear
of potential serious adverse effects based on the available evidence.
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INTRODUCTION
Creatine is a naturally occurring compound composed of three amino acids: glycine,
arginine, and methionine. Approximately 95% of creatine is found within skeletal muscle, with
the remainder being found in the brain and testes (in males). About two-thirds of creatine is
stored as phosphocreatine, with the rest available as free creatine. The average person requires
about 2g of creatine daily to maintain normal stores within the body. For most people (except
those following vegan diets), about half of the daily creatine requirement is fulfilled by foods,
with the other half being synthesized by the liver and kidneys (Kreider et al., 2017).
Creatine works through various and complex pathways. One mechanism of action
involves the hydrolysis of phosphocreatine into creatine and a phosphoryl group, which can be
used to resynthesize adenosine triphosphate (ATP). This is critical for energy production,
particularly during maximal effort exercise such as sprinting or heavy weightlifting. Creatine
also works within the mitochondria to facilitate energy metabolism (Kreider et al., 2017).
According to the International Society of Sports Nutrition, the most effective way to
supplement creatine is to ingest 20g split between four doses for a period of five days (Kreider et
al., 2017). This is the fastest way to fully saturate the body’s creatine stores. From there, a daily
dose of 3-5g will maintain stores in most adults. Some people may experience mild
gastrointestinal distress with the 20g loading dose. An alternative dosing strategy would be to
just start at the 3-5g daily maintenance dose. This dosing protocol may mitigate side effects, but
will delay the full effects of supplementation because saturation may take up to 30 days to be
reached rather than five to seven days with the loading protocol.
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Creatine supplementation increases muscle phosphocreatine concentration, reduces
muscle acidosis and oxidative metabolism, and increases lean body mass. For all these reasons,
creatine has been extensively studied for its use as an ergogenic aid in athletes of all sports,
particularly those involving short bursts of activity. These benefits are well known and discussed
in the realm of athletics (Kreider et al., 2017).
Statement of the Problem
Creatine is used by athletes worldwide; however, creatine has also been studied for
numerous other potential benefits in both general and disease-specific populations. These results
are not nearly as well known, and creatine is not widely used outside of the athlete population.
Clinicians may be missing opportunities to utilize creatine, which is a cheap, over-the-counter
nutritional aid. Additionally, there is often concern voiced over the safety of creatine
supplementation, often citing deleterious effects on hydration, kidney function, or overall health.
These concerns may not be founded in actual scientific evidence.
Research Questions
1. Does creatine supplementation provide benefit in any patient populations besides
athletes?
2. Is creatine supplementation safe?
Creatine has been studied as a potential treatment for many diseases with varying degrees of
success. This study will focus on some of the areas where creatine shows potential for benefit to
the largest population of patients. Diseases that are exceedingly rare or where creatine was
altogether not beneficial will be spared in the interest of brevity.
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REVIEW OF LITERATURE
Methodology
References were collected through a review of PubMed and Scopus databases. In
PubMed, the following MeSH terms were used: “creatine monohydrate AND supplementation”,
“creatine monohydrate AND safety”, “creatine AND depression”, “creatine AND diabetes”,
“creatine AND glycemic control”, “creatine AND osteoarthritis”, “creatine AND kidney
function”, “creatine AND adverse effects”, “creatine AND therapeutic uses”. Scopus was
searched with “creatine monohydrate”, “creatine uses”, and “creatine safety”. Where possible,
trials with human subjects were utilized. Studies that focused on creatine’s effects in athletes or
weightlifting parameters were eliminated. Topics were further narrowed down by conditions
with the most amount of research and medical concerns recognized as commonly seen in primary
care.
Psychological Disorders
Major depressive disorder (MDD) is treated most commonly with selective serotonin
reuptake inhibitor (SSRI) pharmacotherapy. One of the major drawbacks to this class of
medication is the delayed onset of therapeutic relief of depression symptoms. According Lyoo et
al. (2012), this may take several weeks. Of the studies utilizing creatine supplementation in
patients with depression, the two most prevalent were earlier treatment response and increased
brain phosphocreatine (PCr).
Lyoo et al. (2012) reported patients with MDD have been found to have lower brain
levels of phosphocreatine. Additionally, patients who responded positively to depression
treatment have shown subsequent normalization (increase) of their phosphocreatine levels.
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Kondo et al. (2011) utilized magnetic resonance spectroscopy, the only in vivo method able to
quantify brain levels of phosphocreatine, in order to measure the effects of creatine
supplementation in female adolescents with MDD resistant to traditional SSRI therapy. Five
adolescent females with SSRI-resistant MDD currently treated with fluoxetine were recruited.
Utilizing the Children’s Depression Rating Scale-Revised (CDRS-R), patients’ raw scores were
greater than or equal to 40, despite treatment. The patients had 31-phosphorus magnetic
resonance spectroscopy performed at baseline and after eight weeks of supplementation with a
daily dose of 4g creatine. For comparison, a group of six healthy females were imaged eight
weeks apart. The creatine group saw a significant increase in PCr after 8 weeks (.151 vs. .161,
p=.02), while the healthy controls saw no change. Additionally, average CDRS-R score went
from 69 (SD 9.69) to 30.6 (SD 8.50) during that same time, a drop of 56%. Though a small
sample size, this study demonstrated that increased PCr levels in depression can be correlated to
a reduction in depressive symptoms.
Hellem et al. (2015) also utilized magnetic resonance spectroscopy to monitor PCr
concentration. They studied 14 females with depression and comorbid methamphetamine
addiction. After eight weeks of treatment with a 5g daily dose of creatine, brain PCr levels
increased from 0.223 to 0.233 (p= <.01).
The Hamilton Depression Rating Scale (HAM-D) is a common tool used to rate the
severity of depressive symptoms. Numerous studies have used this tool to evaluate the response
of patients supplemented with creatine. Lyoo et al. (2012) and Hellem et al. (2015) were among
the studies achieving positive results with adjunctive creatine supplementation, while Nemets
and Levine (2013) did not have such definite success.

8

THE SAFETY AND EFFICACY OF CREATINE SUPPLEMENTATION

9

Lyoo et al. (2012) studied females diagnosed with MDD. It was a double-blind placebocontrolled clinical trial and participants were randomly assigned. The first group received
escitalopram plus placebo and the second group received escitalopram plus 3g/day creatine for
the first week and 5g/day thereafter. The primary outcome was measured via HAM-D.
Secondary outcomes were the Montgomery-Asberg Depression Rating Scale (MADRS), and the
Clinical Global Impressions Scale (CGI). Measures were taken initially and weekly thereafter.
Treatment response was defined as a 50% reduction from baseline HAM-D score. Remission
was defined as a HAM-D score of 7 or less.
Participants receiving creatine augmentation showed greater mean improvement on the
HAM-D (-44.9% vs. -24.1%, z= -4.89) as early as week 2. Similar improvements by week 2
were seen on MADRS (z=4.87, p<0.001) and CGI (z=-2.84, p=0.005). By conclusion of the
study at week 8, participants receiving creatine reduced HAM-D score by 79.7% vs. 62.5% for
placebo (z=-3.84, p<0.001). Regarding treatment response, the creatine group showed a
favorable and significant difference at week 2 (odds ratio=16.05, p=0.02) week 4 (OR=16.54,
p=0.001), but not at week 8 (OR=5.01, p=0.17). By week 8, remission was achieved by 13 (52%)
of the creatine group but only 7 (25.9%) in the placebo group (OR=6.92, p=0.008). There were
no statistically different frequencies of adverse events in the two treatment groups, and no
serious adverse events in either group. This study, according to Lyoo et al. (2012), suggests
depression may improve to a greater extent in patients treated with escitalopram receiving
creatine than those receiving placebo as early as two weeks after the initiation of treatment. The
creatine group also demonstrated earlier treatment response and a higher remission rate without
any difference in adverse effects.
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Hellem et al. (2015), as previously mentioned, demonstrated increased PCr levels with
creatine supplementation. Consequently, depression symptoms, measured with the HAM-D
scale, decreased. This study used females with co-morbid methamphetamine addiction. Positive
drug screens for methamphetamine decreased from 50% of participants at baseline to 21.4% by
week 6, though no statistical significance to this decrease was detailed by researchers.
As helpful as creatine appears to be in MDD, it showed no benefit and was potentially
even harmful in other mental health studies. Nemets and Levine (2013) utilized a pilot, dose
finding, 4-week double-blind parallel augmentation study testing eighteen patients with MDD
not responsive to three weeks of antidepressant treatment. The patients were placed into groups
receiving placebo, 5g creatine, or 10g creatine daily in combination with their current
antidepressant medication. After four weeks, there was no difference in HAM-D rating between
the three groups. However, two female patients responded well (>50% reduction in HAM-D
score after two weeks) to creatine augmentation. Overall, the authors concluded creatine
augmentation showed no advantage compared to placebo, although certain subsets of patients
may see a more rapid response.
Levental et al. (2015) studied creatine supplementation in patients with chronic
schizophrenia. Treatment with creatine only mildly improved schizophrenia symptomology and
did not improve cognitive functions. With a sample size of only seven participants, and no
control group, this study did not give convincing evidence to support creatine in patients with
schizophrenia. Toniolo, Fernandes, Silva, da Silva Dias, and Lafer (2016) studied effects of
creatine as adjunctive therapy in bipolar depression. While creatine supplementation showed
mild, but significant improvement in verbal fluency, it also activated hypomania in one patient
and mania in another. Lastly, Roitman, Green, Osher, Karni, and Levine (2007) completed a
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small pilot study of creatine supplementation in patients with unipolar or bipolar depression.
While results were promising for unipolar depression, both participants with bipolar depression
withdrew from the study after developing hypomania or mania. Based on these studies, the
evidence shows creatine only has potential benefit in MDD, and should especially be avoided in
bipolar depression.
Type 2 Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by an
initial state of insulin resistance in the liver and muscle tissue which progresses to impaired
insulin secretion and persistent hyperglycemia (Pinto, Botelho, Pimentel, Campos-Ferraz, &
Mota, 2016). There are many pathophysiological mechanisms which can be involved in the
development of this disease process. Two of them are the glucose transporter (GLUT) and
adenosine monophosphate-activated protein kinase (AMPK). GLUT4 is an insulin-regulated
glucose transporter, most commonly found in muscle and adipose. When glucose is ingested, the
pancreas releases insulin, which binds to the insulin receptor of muscle cells. This sets off a
cascade which moves GLUT4 transporters from within the intracellular space to the plasma
membrane. Once incorporated in the plasma membrane, GLUT4 transporters allow glucose to
move within the cell to be used for energy. In T2DM, insulin resistance and/or subsequent low
circulating insulin means GLUT4 transporters are increasingly sequestered within the
intracellular space, leading to hyperglycemia and the inability for cells to produce energy.
AMPK phosphorylates many target proteins, which in turn stimulate such processes as
stimulation of hepatic fatty acid oxidation, muscle glucose uptake, and modulation of insulin
secretion by pancreatic beta-cells. (Pinto et al. 2016). One way the AMPK signaling system is
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stimulated is via exercise, so it stands to reason control of T2DM may be affected by the level
AMPK stimulation.
Much of the research involving creatine and diabetes or glycemic control has been
completed in different animal studies. A systematic review by Pinto et al (2016) noted the results
were largely divergent, which proves species-specific responses do exist in creatine studies.
Given this analysis, animal studies were not highly weighted or extrapolated to hypothesize
human results.
There are however, two double-blind, randomized trials that examined the effects of
creatine in patients diagnosed with T2DM. Gualano et al. (2011a) and Alves et al. (2012) both
compared creatine supplementation against placebo, with participants in both studies also
undergoing an exercise regimen of both cardiovascular and strength training.
Gualano et al. (2011a) treated patients with T2DM with either a 5g daily dose of creatine,
while the control group was given dextrose. Treatment was blinded to both participants and
researchers until completion of the study. Participants in both groups underwent an exercise
program with three sessions per week. Sessions consisted of 25 minutes of strength training
followed by 30 minutes of cardiovascular exercise. The primary outcome was glycemic control
as assessed by emoglobin A1c (HbA1c). Secondary outcomes included glucose, insulin, and Cpeptide measured in intervals following a standardized meal tolerance test (MTT). The two
groups had no significant difference in baseline HbA1c (p=0.92). After 12 weeks, only the
creatine group showed a mean reduction HbA1c, and the difference between groups was
statistically significant (-1.1%, 95% CI -1.9% to -0.4%, p=.008). There was a significant
reduction in postprandial glycemia in the creatine group at 0 (-48 mg/dl, p=0.001), 30 (-48
mg/dl, p=0.004), and 60 min (-68 mg/dl, p=0.003) compared to the placebo group. Insulin and C-
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peptide measurements showed no significant differences between groups. Muscle GLUT-4
membrane content was also measured, though not as a primary or secondary outcome. At
baseline, there was no significant difference between the creatine and placebo groups. Both
groups increased GLUT-4 content after intervention to the point there was no difference between
each group and the control group (p=0.92). However, the creatine group increased GLUT-4
significantly more than the placebo group (p=0.03). Based on this data, Gualano et al. (2011a)
concluded creatine supplementation, when paired with an exercise regimen, improved glycemic
control in patients with T2DM. This improvement in glycemic control was attributed primarily to
increased muscle GLUT-4 recruitment, resulting in improved cellular energy utilization.
Following the results of Gualano et al. (2011a), another study by Alves et al. (2012)
sought to build on those results and further investigate the link of increased GLUT-4 and
improved glycemic control in patients with T2DM supplemented with creatine. They followed a
similar protocol, dividing groups of patients with T2DM into creatine 5g/day or placebo. This
was paired with a twice-weekly exercise program. Subjects were followed for 12 weeks. A
subset of 10 individuals (4 from placebo group, 6 from creatine group) were selected to have
muscle biopsies performed at baseline and post-intervention. Researches selected four “masterregulators” of insulin and muscle contraction to be measured. Insulin receptor (IR-B), AMPK
alpha (AMPK-a), Akt/protein kinase B (AKT-1), and p42/44 mitogen-activated kinase (MAPK
p42/44) were the regulators chosen.
Results of GLUT-4 were in line with the work of Gualano et al. (2011a), showing an
increase post-intervention. Amongst the regulating proteins, expression of IR-B, AKT-1, and
MAPK p42/44 were unchanged. AMPK-a, however, showed an increase positive correlated with
GLUT-4 (p=<0.001), and was higher in the creatine group vs. placebo, though not quite reaching
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statistical significance (p=.06). AMPK-a was inversely correlated with HbA1c levels (r= -0.68,
p<0.001). GLUT-4 was inversely correlated to HbA1c levels (r= -0.89, p<0.001).
The results from Alves et al. (2012) drilled further down on the work of Gualano et al.
(2011a), attributing the increase in GLUT-4 and subsequent improvement in HbA1c to increased
expression of AMPK-a. Additionally, results suggested this improvement was increased with
creatine supplementation.
While the safety of creatine supplementation will be addressed a topic on it’s own, it is
important to point out none of the studies involving creatine and diabetes or glycemic control
noted any serious adverse events with creatine usage, and there were no significant differences in
adverse effects between placebo and treatment groups. Gualano et al. (2011b) studied kidney
function with creatine use in patients with T2DM. Since these patients are at higher risk for
kidney complications, the authors felt it was important to study to potential side effects of
creatine usage on kidney function. Using the same participant data from Gualano et al. (2011a)
which studied glycemic control, estimated creatine clearance, serum and urinary urea,
electrolytes, proteinuria, and albuminuria were measured. After 12 weeks of intervention, there
were no significant differences in any of these parameters between groups. While it was a small
sample size, it was an important finding, especially with the pre-disposition for those with T2DM
to have kidney problems. This study suggested the safety of creatine supplementation in patients
with T2DM but without chronic kidney disease.
Musculoskeletal Health and Disorders
Given creatine’s well-established effects on muscle strength and function (Neves et al.
2011), it is worth investigating if creatine has additional musculoskeletal benefits. Candow and
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Chilibeck (2010) explored creatine’s potential benefits in regards to bone density in the eldery.
Neves et al. (2011) studied use of creatine in knee osteoarthritis (OA). Lastly, Roy, de Beer,
Harvey, and Tarnopolsky (2005) studied its use in recovery from total knee replacement.
Candow and Chilibeck (2010) noted, “aging is associated with a reduction in bone mass
(i.e. 0.5% per year after the age of 40).” The authors also report physical activity is the only
current proven strategy to increase bone mass and bone strength while reducing risks of falls in
the elderly. The mechanism by which resistance training improves bone formation is mechanical
strain applied to bone via muscle hypertrophy (Candow & Chilibeck, 2010). Despite these
benefits, even those who continue resistance training with advancing age are prone to
experiencing bone loss. Since creatine supplementation is associated with increased muscle
mass, and muscle mass is a predictor of bone mass, it was hypothesized creatine may be
associated with increased bone mass. The authors also pointed out creatine, when added to a
culture medium, increased metabolic activity of osteoblast-like cells and production of
osteoprotegerin, which inhibits osteoclast differentiation. If creatine behaved similarly within the
human body, the results would be increased bone mass and density. One common marker of
bone resorption used in studies is N-telopeptides, which are inversely related to bone density.
Candow and Chilibeck (2010) reviewed nine studies related to bone density and creatine
supplementation. The studies varied in parameters such as subject age, creatine dosage, duration,
exercise program (or not), and outcomes to measure bone density and/or mass. Of the nine
studies compiled, five showed an improvement in either bone density or resorption, including
four studies showing decreased N-telopeptides.
Conversely, four studies of those compiled did not show any improvement between
groups in bone density or resorption, though it is worth noting that only one study measured N-
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telopeptides. Given these equivocal results, the authors determined they were unsure if creatine
supplementation improved bone density or mass via increased production. They were, however,
more positive on the potential for creatine to improve bone maintenance via decreased
resorption. Further research was suggested to investigation creatine’s benefits on bone in
humans.
Another potentially useful effect for creatine is in OA. Neves et al. (2011) sought to
investigate whether creatine’s positive effects on muscle would lead to improvement in arthritis
symptoms. The authors reported previous research had proven quadriceps weakness is associated
with functional impairment in OA, and muscle strength may prevent further progression of
existing OA. The authors also pointed to the evidence of strengthening exercises in knee OA and
hypothesized any treatment enhancing exercise’s muscle strengthening effect could be
therapeutic for patients with knee OA. A 12 week, double-blind, randomized control trial with 26
participants diagnosed with knee OA was performed. Participants in the creatine group received
a loading dose of 20g for the first 7 days, and 5g daily thereafter. The placebo group received
equal doses of dextrose. A structured exercise program was performed three times per week by
both groups. The primary outcome was a timed-stands test evaluating how many times the
participant could stand-up from a chair in 30 seconds. Secondary outcome included a function,
pain, and stiffness assessment validated by the Osteoarthritis Research Society, a 10 question
quality of assessment, and muscle strength and body composition measurements. Only the
creatine group improved on the primary outcome (creatine: pre= 15.7, post= 18.1, placebo: pre=
15.0, post 15.2, p=0.04). Both groups showed significant reductions in pain, but only the creatine
group improved in stiffness and physical function (p= 0.024 and p= 0.005, respectively). The
creatine group improved on qualify of life assessment while the placebo group did not (p= 0.01).
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No significant differences were noted in muscle strength (p= .081), however, the creatine group
did show a significant increase in lower limb lean mass (p= 0.04). No adverse effects or
differences in kidney function were discovered in either group (p= 0.72). This study
demonstrated creatine’s potential benefits in physical function and quality of life parameters in
patients with OA.
With creatine showing promise in reducing bone resorption in the elderly as well as
function in those with OA, another avenue to explore was its role in patients undergoing knee
surgery, particularly total knee arthroplasty (TKA). Roy, Beer, Harvey, and Tarnopolsky (2005)
selected 37 adults undergoing TKA and supplemented them with either 10g creatine/day presurgery and 5g/day for 30 days post-surgery or placebo. Primary outcomes measured were body
composition via DEXA scan and quadriceps, ankle, and handgrip strength. Results no statistical
difference between groups for any of the primary outcomes. Creatine does not appear to useful
for patients undergoing TKA.
Safety of creatine supplementation
For years, creatine has been best known for its use in athletes. However, creatine has
acquired a dubious reputation thanks in part to what Kim, Kim, Carpentier, and Poortmans
(2011) say are “doubtful allegations of adverse effects of creatine supplementation…released
through the press media and through scientific publications.” While anecdotal reports exist
detailing muscle cramps, gastrointestinal complaints, liver or kidney damage with creatine
supplementation, little research exists proving harmful effects. As previously mentioned,
Gualano et al. (2011b) found no effects on kidney function in patients with T2DM who
supplemented with creatine. Genc et al. (2014) also studied effects of creatine and kidney
function, though in rats. The researchers in this study induced kidney damage in two groups with
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cisplatin, a nephrotoxic substance. One group was given cisplatin only, the other group was
given cisplatin and 300 mg/kg of creatine for 30 days after the cisplatin injection. A third group
of healthy rats was used as control. BUN and creatinine levels, histopathology evaluation, and
body weights were outcomes measured. The cisplatin only group showed decreased weight,
impaired BUN and creatinine levels, and histopathological changes. The cisplatin and creatine
group, when compared to the cisplatin only group, had less weight loss and better BUN,
creatinine, and histopathology scores (p<.05). Despite this, both groups fared worse than the
healthy control group. This study demonstrated creatine was not just neutral, but rather
nephroprotective against the toxic effect of cisplatin.
Kim et al. (2011) reviewed research tied to many anecdotal complaints of creatine’s
adverse effects. The authors found five total studies looking at muscle cramping with creatine
use. None of the studies found muscle cramping was caused by creatine supplementation. The
authors suggested the intensity of the exercise being performed may be the culprit rather than
creatine. As for gastrointestinal (GI) complaints, two small studies reported some side effects of
GI distress. The first study had subjects consuming 40g of creatine per day, a higher than normal
dosing load, in addition to 400mg of caffeine. The other study had athletes consuming 6-8mg
creatine per day for up to 3-5 months, which is again a slightly higher dosing strategy than other
studies. Three other studies reported no GI side effects, even with doses as high as 20g per day.
The authors concluded there was insufficient evidence to support the notion of creatine causing
GI problems. Liver dysfunction was studied next, looking at alkaline phosphatase, aspartate
transaminase, alanine transaminase, and gamma glutamyl transpeptidase markers in numerous
studies. Dosing protocols ranged from 20g daily for 5 days up to 10g daily for 5 years. No
evidence of detrimental effects of liver function were discovered. Lastly, complaints of kidney
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impairment were investigated. After thorough review, the authors concluded kidney function was
not affected by creatine supplementation using short-term doses up to 20g daily or by long-term
doses of 10g/day or less thereafter. (Kim et al., 2011)
The International Society of Sports Nutrition (ISSN) offered a position stand on the
safety and efficacy of creatine supplementation authored by Kreider et al. (2017). The position
stand offers many possible therapeutic roles of creatine supplementation, but for purposes of this
literature review, the focus will be on the ISSN’s position on the safety of creatine. The ISSN
reports the only consistent side effect reported in over 1,000 studies reviewed in weight gain.
This weight gain is explained by creatine’s osmotic effect. As creatine’s concentration within the
body increases, the body maintains more water, usually in the range of 0.5-1.0 liters (Kreider et
al. 2017). Beyond this side effect, the ISSN reports studies as involving at least 30g per day for
up to 5 years have been conducted without any additional side effects reported. Beyond that, the
authors not only refute the claims that creatine may cause dehydration, muscle injuries, renal
injury, or liver dysfunction, but point out that creatine may reduce the incidence of many of these
side effects. Going back to the osmotic effect of creatine, Kreider et al. (2017) note creatine has
shown potential benefit in enhancing tolerance to heat as well as preventing muscle injury or
cramping.
Lastly, the ISSN’s position stand also acknowledges many manufacturer’s age
recommendations (18 and older) are not founded in evidence, but rather in liability management.
They state there is no scientific evidence showing harm of creatine supplementation in infants,
children or adolescents. Furthermore, there are some rare conditions involving inborn errors of
creatine metabolism in which creatine supplementation is vital for survival. Kreider et al. even
go as far to point out creatine supplementation may have some benefits in pregnancy, especially
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when there is hypoxic insult to the fetus. While it is admitted that further research must be done,
the authors believe creatine supplementation may be beneficial for fetal growth and
development.
DISCUSSION
Creatine supplementation increased phosphocreatine saturation in the brain, reduced time
to efficacy when used as an SSRI adjuvant, and ameliorated symptoms of depression in
numerous studies. Creatine supplementation showed improved glycemic control as measured by
HbA1c and glucose area under the curve when combined with exercise in patients with T2DM.
Creatine supplementation showed improved muscle function and decreased pain in patients with
knee OA. There is also evidence that shows creatine may reduce the rate of bone resorption in
the elderly. Creatine does not offer functional benefits in recovery from total knee arthroplasty.
Creatine is safe for use in all tested dosage ranges and for use up to several years. At typical
doses, it is safe for use in virtually all patient populations.
Does creatine supplementation provide benefit in any patient populations besides athletes?
Psychological Disorders.
Creatine’s presence in the brain, as phosphocreatine, has been established via studies using
magnetic resonance spectroscopy. Creatine supplementation has shown to increase brain
phosphocreatine concentrations, and increased phosphocreatine concentrations have been
associated with amelioration of depression symptoms (Kondo et al., 2011). In patients with
MDD who have achieved treatment success, a normalization (increase) of phosphocreatine levels
has occurred (Lyoo et al., 2012). The studies conducted to this point regarding creatine
supplementation and MDD have either been small sample sizes or even pilot studies. In order for
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creatine to gain a foothold amongst other plausible depression treatments, larger studies are
needed. In addition, almost all studies were 12 weeks or less in duration. A longer-term study
would be beneficial in determining if the positive effects of creatine supplementation continue
with further treatment.
While creatine’s effects for MDD (a unipolar depression) are positive in nature, it’s
effects on bipolar depression are quite the opposite. MDD is defined by a patient’s persistent
feelings on one end of the emotional spectrum, and an increase of cerebral phosphocreatine
brings the patient back towards a euthymic state. What was seen in bipolar depression, however,
was that creatine supplementation does stabilize mood regardless where it falls on the spectrum.
Instead, it may be a mood activating substance (Roitman et al. 2007), which is not conducive for
bipolar patients who are prone to manic or hypomanic states. This is an important distinction for
clinicians to make.
Creatine was not shown to be beneficial for primary outcomes in patients with negative
symptom schizophrenia (Levental et al., 2015). There were small improvements in some
secondary outcomes, but conclusions were limited by small sample size of the study. No adverse
or negative effects were seen in treatment of schizophrenia with creatine.
In patients with comorbid methamphetamine addiction and depression, creatine
supplementation showed improved depression symptoms as well as reduced methamphetamine
use (Hellem et al., 2015). Other studies have proven benefits of creatine supplementation in
treatment of depression (Lyoo et al., 2012) without co-morbidities, so the next logical step would
be to trial creatine supplementation in methamphetamine users without comorbid depression. It
is plausible methamphetamine use affects phosphocreatine stores in the brain, but the magnitude
of this effect is still uncertain.
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Type 2 Diabetes Mellitus.
Perhaps the most promising and consistent benefit of creatine supplementation is that of
improved glycemic control when paired with exercise. Gualano et al. (2011a) and Alves et al.
(2012) came to the same conclusion that creatine supplementation and a structured exercise
program significantly improved glycemic control as measured by HbA1c. Furthermore, Gualano
et al. (2011) identified increased muscle GLUT-4 membrane content as the mechanism by which
this improved glycemic control was achieved. Alves et al. (2012) built on this research by
identifying APMK-a as the signaling protein responsible for bringing GLUT-4 receptors from
the intracellular space into the membrane.
Gualano et al. (2011b) showed creatine did not impair kidney function in patients with
T2DM. This is an important distinction due to the end-organ damage T2DM can cause, including
on the kidneys. Given that diabetes is a chronic, usually lifelong disease, another means by
which to improve glycemic control that comes without serious cost or side effects, it is important
for further research to be conducted to maximize the potential of creatine as a treatment for
T2DM.
Musculoskeletal Disorders.
The majority of evidence supporting benefits of creatine supplementation is related to
increased athletic performance, lean muscle mass, and recovery from short, intense exercise
(Kreider et al., 2017). It is also established that creatine supplementation has a synergistic effect
when combined with exercise. Therefore, the results seen with patients with knee OA can be
explained by creatine supplementation synergistically working with an exercise program to
increase lower limb lean mass, muscle strength, and physical function (Neves et al., 2011).
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Further research would be needed to confirm this effect in OA of other joints. Neves et al. (2011)
also commented muscle weakness and/or atrophy is often a precursor to OA. Reduced support
from the surrounding musculature results in increased stress on the joint itself, which leads to
deterioration and eventually OA. The authors went to speculate creatine supplementation, paired
with a structure exercise program, could be used in a prophylactic manner to either prevent OA
or stop the progression of symptoms.
Besides OA, creatine also showed potential as a treatment to decrease bone resorption in the
elderly. This effect was most commonly seen when paired with exercise (Candow & Chilibeck,
2010), with increased lean mass leading to increased mechanical tension and subsequent
decrease in excretion of osteoclastic biomarkers. OA and decreased bone density are two very
common problems in the elderly population, making this research important for geriatric
patients.
In regards to musculoskeletal health, one area creatine did not show benefit was in knee
strength or recovery when used in the peri-surgery window for total knee arthroplasty (Roy et al.,
2005). The authors speculated patients need to exceed a minimum threshold of activity to
increase uptake of creatine into the muscle.
Is creatine supplementation safe?
The evidence regarding creatine supplementation consistently shows it is safe for use in
almost any population, at any dose, for any duration. Certainly there are limitations, but doses far
above what was used in the themes discussed in this study have been studied without serious or
long-term adverse effects. Duration of studies go at least 5 years in length (Kreider et al., 2017),
again without adverse effects noted. The only potential side effect consistently noted was weight
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gain, which was directly attributed to increases in lean mass, whether it be water retention from
the osmotic effect of creatine or increased muscle mass. Kim et al. (2011) found no conclusive
evidence of liver or kidney dysfunction, even in studies lasting up to 5 years. Muscle cramping
and gastrointestinal distress were also determined to be unfounded anecdotal evidence or
inconclusive at very least. Lastly, Kreider et al. (2017) stated age requirements on creatine
packaging are manufacturers recommendations only and not based on any clinical evidence.
Creatine, to this point, has been found to be safe in adolescents, infants, and even pregnancy.
Furthermore, there are possible further benefits in specific disease states in these populations
which would be worthy of additional study.
APPLICABILITY TO CLINICAL PRACTICE
Depression, diabetes, osteoarthritis, and reduced bone density are very common problems
seen in primary care. Virtually all primary care providers seeing and treating many patients
affected by these chronic conditions. It is reasonable to think many of these patients would
possibly benefit from creatine supplementation. There are multiple areas of resistance that might
be met when trying to implement what has been learned in this project into practice. First and
foremost, creatine is an over-the-counter supplement, which poses problems of product quality
and purity. Patients can been given advice about reputable brands with reputation of good
manufacturing practices, but ultimately supplements are not subject to FDA standards
prescription drugs are manufactured under. Secondly, patients may not be familiar with or know
anyone who takes creatine, or worse yet, may have a very negative feeling based on the
aforementioned case studies or anecdotes questioning its safety. Try as one might to educate, it
may be futile if the patient is not open to believing the evidence with which they are presented.
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Those challenges being noted, the evidence to date overwhelmingly shows creatine is a
safe supplement for essentially anyone to use. It has been studied in many dosage ranges and for
many years of long-term use. After completing this study, practitioners should feel comfortable
prescribing creatine to almost any patient without hesitation in regards to its safety.
Beyond its safety, creatine shows good potential for benefit in many circumstances.
Having a tool to potentially shorten the all-too-problematic waiting period between initiation of
SSRIs and the actual onset of relief is very enticing. Furthermore, there is a stigma associated
with antidepressants that turns many patients off from using them. A naturally occurring
substance may be more amenable to their treatment plan. It is imperative, however, for the
clinician to have a proper diagnosis prior to initiating treatment with creatine, especially when
differentiating between a unipolar or bipolar depression. As beneficial as creatine may be in
MDD, it can be mania-inducing in bipolar depression.
In many patients, especially the elderly, the potential benefits of decreased bone
resorption and improvement of OA symptoms has the potential to really impact quality of life.
Bone and joint problems are becoming increasingly prevalent as obesity continues to increase in
the United States.
Patients with diabetes might be interested to try a nonpharmacological option that shows
promise of being almost as potent as some pharmacological agents, but without the side effect
profile or associated cost. Furthermore, the synergistic effect between creatine and exercise is yet
another reason to encourage positive lifestyle habits in T2DM.
Further research is likely needed before creatine becomes a staple of treatment plans.
However, the potential benefits and lack of adverse effects make creatine worth trying,
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especially if other traditional therapies fail and the clinician is struggling with treating one of the
previously listed conditions.
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